Zyclara
Molluscum Contagiosum, Condylomata Acuminata, Carcinoma, Basal Cell + 3 more
Treatment
8 FDA approvals
0 Active Studies for Zyclara
Treatment for
Molluscum Contagiosum
What is Zyclara
Imiquimod
The Generic name of this drug
Treatment Summary
Imiquimod is a medication used to treat genital and anal warts. It works by activating an immune response in the body which helps control the production of warts. Imiquimod does not actually treat the virus that causes warts, but it can help reduce their appearance. This medicine can also be used to treat actinic keratoses, a skin condition on the face and scalp, and certain types of skin cancer.
Aldara
is the brand name
Zyclara Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Aldara
Imiquimod
1997
27
Approved as Treatment by the FDA
Imiquimod, also known as Aldara, is approved by the FDA for 8 uses like Face and Actinic Keratoses of the scalp .
Face
Actinic Keratoses of the scalp
Actinic Keratoses of the face
Superficial Basal Cell Carcinoma
Condylomata Acuminata
Scalp structure
Carcinoma, Basal Cell
Condylomata Acuminata
Effectiveness
How Zyclara Affects Patients
Imiquimod is a medicine that helps to control the growth of warts on the skin of the genital and anal areas. This medication does not get rid of warts, and new warts may appear during treatment. It works by stimulating the body's own immune system to fight the virus that causes warts. Imiquimod is not used for warts inside the vagina, penis, or rectum. It can also be used to treat actinic keratoses, a skin condition of the face and scalp, and certain types of skin cancer called superficial basal cell carcinoma. This medicine is especially useful for treating areas of
How Zyclara works in the body
Imiquimod works by stimulating the body's immune system to fight disease. It does not directly target viruses, but it triggers the release of cytokines and interferons, which are molecules that help the body fight off infections. In treating basal cell carcinoma, it works by activating toll-like receptor-7, altering the immune response and causing diseased cells to die off. It also increases the movement of lymphocytes, dendritic cells, and macrophages into the tumor.
When to interrupt dosage
The quantity of Zyclara is contingent upon the identified disorder, including Communicable Diseases, Face and Superficial Basal Cell Carcinoma. The measure of dosage is contingent upon the approach of administration (e.g. Cream - Topical or Topical) as specified in the table below.
Condition
Dosage
Administration
Face
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Cream - Cutaneous, Cutaneous, Gel - Topical, Gel
Condylomata Acuminata
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Cream - Cutaneous, Cutaneous, Gel - Topical, Gel
Carcinoma, Basal Cell
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Cream - Cutaneous, Cutaneous, Gel - Topical, Gel
Communicable Diseases
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Cream - Cutaneous, Cutaneous, Gel - Topical, Gel
Molluscum Contagiosum
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Cream - Cutaneous, Cutaneous, Gel - Topical, Gel
Scalp structure
, 0.05 mg/mg, 0.125 mg/mg, 3.75 %, 5.0 %, 2.5 %, 0.0375 mg/mg, 0.0025 mg/mg, 0.025 mg/mg
, Topical, Cream - Topical, Cream, Cream - Cutaneous, Cutaneous, Gel - Topical, Gel
Warnings
Zyclara has a single contraindication, thus it should not be employed when afflicted with any of the conditions outlined in the below table.
Zyclara Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 6 known major drug interactions with Zyclara.
Common Zyclara Drug Interactions
Drug Name
Risk Level
Description
Allogeneic processed thymus tissue
Minor
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Imiquimod.
Inebilizumab
Minor
The risk or severity of infection can be increased when Imiquimod is combined with Inebilizumab.
Vibrio cholerae CVD 103-HgR strain live antigen
Minor
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Imiquimod.
Haloperidol
Moderate
The serum concentration of Haloperidol can be increased when it is combined with Imiquimod.
Magnesium
Moderate
The serum concentration of Magnesium can be decreased when it is combined with Imiquimod.
Zyclara Toxicity & Overdose Risk
Overdosing on ibuprofen can cause flu-like symptoms like fever, exhaustion, headache, nausea, diarrhea, and muscle pain.
Zyclara Novel Uses: Which Conditions Have a Clinical Trial Featuring Zyclara?
Nine active studies are presently evaluating the potential of Zyclara to ameliorate Molluscum Contagiosum, Facial and Condylomata Acuminata.
Condition
Clinical Trials
Trial Phases
Condylomata Acuminata
0 Actively Recruiting
Carcinoma, Basal Cell
0 Actively Recruiting
Scalp structure
0 Actively Recruiting
Molluscum Contagiosum
1 Actively Recruiting
Phase 3
Communicable Diseases
0 Actively Recruiting
Face
0 Actively Recruiting
Zyclara Reviews: What are patients saying about Zyclara?
5
Patient Review
2/24/2016
Zyclara for Roughened Red Patches of Skin due to Sun Exposure
4.7
Patient Review
8/20/2015
Zyclara for Superficial Basal Cell Carcinoma of the Skin
4.3
Patient Review
1/30/2015
Zyclara for Superficial Basal Cell Carcinoma of the Skin
4
Patient Review
8/22/2014
Zyclara for Roughened Red Patches of Skin due to Sun Exposure
4
Patient Review
6/20/2015
Zyclara for Roughened Red Patches of Skin due to Sun Exposure
4
Patient Review
6/11/2016
Zyclara for Superficial Basal Cell Carcinoma of the Skin
3.7
Patient Review
9/3/2014
Zyclara for Roughened Red Patches of Skin due to Sun Exposure
3.7
Patient Review
9/1/2015
Zyclara for Roughened Red Patches of Skin due to Sun Exposure
3.3
Patient Review
9/16/2020
Zyclara for Superficial Basal Cell Carcinoma of the Skin
3
Patient Review
2/15/2018
Zyclara for Roughened Red Patches of Skin due to Sun Exposure
2.3
Patient Review
7/21/2014
Zyclara for Roughened Red Patches of Skin due to Sun Exposure
1.3
Patient Review
2/9/2015
Zyclara for Superficial Basal Cell Carcinoma of the Skin
Patient Q&A Section about zyclara
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How much does Zyclara cost?
"The price of Zyclara topical cream 3.75% varies depending on the pharmacy, but is typically around $1,307 for a supply of 7.5 grams. This price is for cash paying customers only and does not include insurance plans."
Answered by AI
How long does it take for Zyclara to work?
"The effects of Zyclara can take 5-7 days to start appearing, and usually stop around day 10. However, stopping the medication can result in the intensification of symptoms for several days afterwards, as it is difficult to immediately stop the medication's effects. Zyclara can also cause flu-like symptoms because it stimulates an immune response."
Answered by AI
How long do you use Zyclara?
"Adults and children 12 years of age and older can use Zyclara® by applying a thin film to the wart once a day at bedtime. The maximum amount of time it can be used is 8 weeks or until the wart is gone. Children younger than 12 years of age need a doctor to determine the amount they should use."
Answered by AI
What is Zyclara cream used for?
"Zyclara is a cream that is used to treat actinic keratoses and external genital or perianal warts. It comes in two strengths, 2.5% or 3.75%. Zyclara Cream works by stimulating the immune system to fight the infections. It is for people 12 years of age and older."
Answered by AI